Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Fineline Cube Jul 17, 2026
Company Deals

Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline

Fineline Cube Jul 17, 2026
Company Deals

China Resources Pharmaceutical to Acquire 23.5% Stake in Lier Chemical to Advance Synthetic Biology Pipeline

Fineline Cube Jul 16, 2026
Company Deals

Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset

Fineline Cube Jul 16, 2026
Company Deals

WuXi Biologics Enters CDRMO Partnership with CANbridge Through 2028

Fineline Cube Jul 16, 2026
Policy / Regulatory

China’s CDE Releases Draft Guideline for Real-World Evidence-Based Pediatric Indication Expansion of Marketed Drugs

Fineline Cube Jul 16, 2026
Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Fineline Cube Jul 17, 2026
Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Fineline Cube Jul 17, 2026
Company Deals Drug

Bioray Biopharmaceutical Expands to Turkey with Three Key Drugs, Marking International Milestone

Fineline Cube Mar 31, 2025

Zhejiang Bioray Biopharmaceutical Co., Ltd. announced on March 31 that it has reached a collaboration...

Company

EClinCloud Secures New Funding to Accelerate AI Innovation in Clinical Research

Fineline Cube Mar 30, 2025

EClinCloud (Ningbo) Technology Co., Ltd., a leading AI technology company specializing in clinical research solutions,...

Medical Device Policy / Regulatory

China Tightens Medical Device Quality Oversight: 2025 Inspection Plan Unveiled

Fineline Cube Mar 29, 2025

China’s National Medical Products Administration (NMPA) has released its 2025 medical device inspection plan, outlining...

Policy / Regulatory

Policy Analysis: Shanghai’s 2025 Pharmaceutical Procurement Regulation and Market Implications

Fineline Cube Mar 29, 2025

Shanghai’s Medical Centralized Bidding and Procurement Affairs Management Office has released its January 2025 list...

Policy / Regulatory

Guangdong Accelerates Centralized Procurement for Apixaban and Key Therapeutics

Fineline Cube Mar 29, 2025

The Guangdong Drug Trading Center has issued a critical update on preparations for the centralized...

Medical Device Policy / Regulatory

China Unveils 2025 Medical Device Inspection Strategy to Tighten Quality Control

Fineline Cube Mar 29, 2025

China’s National Medical Products Administration (NMPA) convened a pivotal conference in Chengdu on March 24...

Company Deals Drug

Eisai Transfers Pariet Rights in China to CBC Group-Controlled Peak Pharma

Fineline Cube Mar 29, 2025

Japan-based Eisai (TYO: 4523) announced a strategic decision to transfer the rights of its proton...

Company Drug

Sinovac Biotech’s SNA02-48 Gains Clinical Approval for Tetanus Prevention

Fineline Cube Mar 29, 2025

Beijing Sinovac Biotech Co., Ltd’s (NASDAQ: SVA) subsidiary Sinovac Life Sciences Co., Ltd. and its...

Policy / Regulatory

Shanghai Designates Backup Suppliers and Specialized Drug Formulations in GY-YD2024-2 Procurement

Fineline Cube Mar 29, 2025

Shanghai has finalized its list of second-tier backup suppliers and manufacturers for specialized drug formulations...

Company Medical Device

Abbott Laboratories’ Volt PFA System Receives EU CE Mark for Atrial Fibrillation Treatment

Fineline Cube Mar 28, 2025

US-based Abbott Laboratories (NYSE: ABT) has announced the receipt of the CE mark in the...

Company Deals

Alcon Laboratories Acquires Majority Stake in Aurion Biotech to Advance Eye Disease Cell Therapy

Fineline Cube Mar 28, 2025

US-based eye care firm Alcon Laboratories, Inc. has announced the acquisition of a majority stake...

Company Drug

Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment

Fineline Cube Mar 28, 2025

Denmark-based Genmab A/S (NASDAQ: GMAB) has secured approval from the Japan Ministry of Health, Labour...

Company

CStone Pharmaceuticals Reports 2024 Results with License Fee Growth Offsetting Drug Sales Decline

Fineline Cube Mar 28, 2025

China-based CStone Pharmaceuticals (HKG: 2616) reported its 2024 financial results and recent business highlights. Revenues...

Company Deals Drug

TransThera and Akeso Biopharma Collaborate on HCC Study with Tinengotinib and Bispecific Antibodies

Fineline Cube Mar 28, 2025

Chinese companies TransThera Sciences (Nanjing) Inc. and Akeso Biopharma (HKG: 9926) have formed a strategic...

Company Drug

NMPA Approves Qingfeng’s Suraxavir Marboxil for Influenza A and B Treatment

Fineline Cube Mar 28, 2025

China’s National Medical Products Administration (NMPA) has approved suraxavir marboxil, a Category 1 drug developed...

Company

Medtronic Launches Digital Innovation Base in Beijing’s BioPark

Fineline Cube Mar 28, 2025

US-Irish firm Medtronic (NYSE: MDT) has inaugurated its digital medical innovation base at the BioPark...

Company Drug

Huadong Medicine Gains NMPA Approval for HDM3019 Rheumatoid Arthritis Trial

Fineline Cube Mar 28, 2025

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced receiving approval from the National Medical Products...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 32.9% Revenue Growth in 2023

Fineline Cube Mar 28, 2025

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) released its 2023 financial report, recording HKD 1.4...

Company

RemeGen’s 2024 Revenue Soars 58.54% on Strong Product Sales and R&D Growth

Fineline Cube Mar 28, 2025

China-based biotech RemeGen Co., Ltd (HKG: 9995, SHA: 688331) released its 2024 financial report, recording...

Company

JW Therapeutics Sees 9% Revenue Decline in 2024 Amid Commercial Strategy Shift

Fineline Cube Mar 28, 2025

China-based JW Therapeutics (HKG: 2126) released its 2024 financial report, recording RMB 158.2 million (USD...

Posts pagination

1 … 217 218 219 … 696

Recent updates

  • Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression
  • Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy
  • Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs
  • Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients
  • Jasper Therapeutics Completes Acquisition of Kira Pharmaceuticals in All-Stock Transaction, Secures $132M Private Placement for Complement Therapies Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Eli Lilly to Acquire AtaiBeckley for $3.8 Billion, Accelerating Psychedelic Therapeutics Development for Treatment-Resistant Depression

Company Drug

Novartis’ Fabhalta Receives FDA Approval as First Oral Complement Factor B Inhibitor to Slow Renal Decline in Primary IgA Nephropathy

Company Drug

Shionogi’s Fetroja Receives FDA Acceptance for Pediatric sNDA Expanding Use to Gram-Negative Infections in Hospital-Acquired Pneumonia and Complicated UTIs

Company Drug

Merck’s Lipfendra Receives FDA Approval as First Oral PCSK9 Inhibitor for LDL Cholesterol Reduction in Hypercholesterolemia Patients

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.